Discover how health economics can support successful Medical Device launch, proposition development, and market access This webinar offers an insightful journey into the world of medical device market access. Specialists...
Read More
Discover our top picks for must-attend sessions at the World EPA Congress 2025 in Amsterdam. Enhance your understanding of core topics with our recommended pre-reading materials
We are delighted to announce that Clare Foy (Director – Global Market Access), Hannah Palin (Director – Local Market Access), and Calum Jones (Associate Director – Health Economics) will be...
Read More
Global healthcare faces growing pressures. We explore how HEOR is evolving in 2025 to deliver value, meet payer needs, and support market access decisions.
Will Battershill and Hollie Wheat from Delta Hat discuss key insights into HTA decision-making from ISPOR Europe. Will explores the hot topic of incorporating patient and carer perspectives into decision-making, whilst Hollie dives into the use of surrogate endpoint evaluation in HTA decision-making.
Discover our tailored health economics training for Pharma and Medtech teams. Delivered by experts, it combines practical insights with real-world experience.
Challenges for orphan medicines entering the European market – Part 3: Economic evidence development
In this four-part series, we will explore the various challenges facing orphan medicines entering the European market and offer solutions that can help improve patient access. In Part 3 of...
Read More
Challenges for orphan medicines entering the European market – Part 2: Clinical evidence development
In this four-part series, we will explore the various challenges facing orphan medicines entering the European market and offer solutions that can help improve patient access. In Part 2 of...
Read More
Are you unsure about some of the terminology used by specialists who are preparing your evidence dossier? Here our experts answer some of the most frequently asked questions about systematic literature reviews and network meta-analysis.
What is the EU Joint Clinical Assessment (JCA) and what does it mean for market access and reimbursment in Euorpe?
